Health Economics›Multiple myeloma›First-line therapy doublets

First-line therapy doublets

Multiple myeloma · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Thalidomide and Dexamethasone (TD) Variant #12	—	R 57 486	29d	28.2 mo	110.0 mo	30	R 1 724 587 PFS proxy	1
Lenalidomide and Dexamethasone (Rd) Variant #09	—	R 14 094	35d	25.5 mo	63.8 mo	23	R 324 159 PFS proxy	15
Bortezomib and Dexamethasone (Vd) Variant #01	—	R 8 080	28d	14.7 mo	—	16	R 129 274 PFS proxy	—
Bortezomib and Prednisone (VP) Variant #01	—	R 4 359	90d	—	—	—	—	—
Lenalidomide and Prednisone (RP) N/A - secondary systemic drug	—	R 0	28d	~37.5 mo	—	~41	~R 0 PFS proxy · indirect	1

5 of 5 regimens shown